Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||43.07%||Sales Growth - Q/Q||27.68%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-80.97%||ROE||156.1%||ROI||-102.16%|
|Current Ratio||2.13||Quick Ratio||2.09||Long Term Debt/Equity||5.49||Debt Ratio||-0.4|
|Gross Margin||91.55%||Operating Margin||-615.77%||Net Profit Margin||-774.12%||Dividend Payout Ratio|
|Cash From Financing Activities||-220 K||Cash From Investing Activities||49.9 M||Cash From Operating Activities||-45.09 M||Gross Profit||8.62 M|
|Net Profit||-35.17 M||Operating Profit||-22.76 M||Total Assets||282.93 M||Total Current Assets||125.04 M|
|Total Current Liabilities||58.68 M||Total Debt||368.43 M||Total Liabilities||429.69 M||Total Revenue||9.39 M|
|High 52 week||24.76||Low 52 week||13.65||Last close||16.79||Last change||2.5%|
|RSI||23.17||Average true range||0.64||Beta||1.52||Volume||4.05 M|
|Simple moving average 20 days||-5.57%||Simple moving average 50 days||-12.22%||Simple moving average 200 days||-20.29%|
|Performance Week||1.63%||Performance Month||-13.01%||Performance Quart||-22.66%||Performance Half||-26.52%|
|Performance Year||3.39%||Performance Year-to-date||-14.64%||Volatility daily||1.91%||Volatility weekly||4.26%|
|Volatility monthly||8.74%||Volatility yearly||30.26%||Relative Volume||263.48%||Average Volume||2.6 M|
|New High||New Low|
2019-11-12 16:05:00 | Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019
2019-11-12 08:02:00 | Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® cabozantinib Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma
2019-11-04 22:59:26 | Edited Transcript of EXEL earnings conference call or presentation 30-Oct-19 9:00pm GMT
2019-10-31 11:45:03 | Exelixis EXEL Q3 Earnings Beat on Strong Cabometyx Sales
2019-10-30 18:45:10 | Exelixis EXEL Q3 Earnings and Revenues Beat Estimates
2019-10-30 16:05:00 | Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update
2019-10-30 08:00:35 | Is There An Opportunity With Exelixis, Inc.'s NASDAQ:EXEL 31% Undervaluation?
2019-10-29 10:40:02 | Exelixis EXEL to Report Q3 Earnings: What's in the Cards?
2019-10-25 10:15:01 | Is Exelixis, Inc. EXEL Going To Burn These Hedge Funds ?
2019-10-23 10:33:02 | Earnings Preview: Exelixis EXEL Q3 Earnings Expected to Decline
2019-10-16 16:05:00 | Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019
2019-10-14 12:08:25 | 7 Under-The-Radar Growth Stocks That Could Benefit New Investors
2019-10-07 11:58:19 | What Kind Of Shareholders Own Exelixis, Inc. NASDAQ:EXEL?
2019-10-07 09:54:01 | Calithera CALA Completes Enrollment in Mid-Stage RCC Study
2019-10-01 11:45:03 | Seattle Genetics Up on Positive Data From Bladder Cancer Study
2019-09-25 16:05:00 | Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
2019-09-23 10:27:02 | Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC
2019-09-16 08:20:59 | Have Insiders Been Selling Exelixis, Inc. NASDAQ:EXEL Shares?
2019-09-13 09:36:01 | Renal Cell Carcinoma Space in Focus: Some Key Developments
2019-09-04 10:17:57 | Biotech vet George Scangos steers new company toward nine-figure IPO
2019-08-26 08:04:48 | These Fundamentals Make Exelixis, Inc. NASDAQ:EXEL Truly Worth Looking At
2019-08-20 23:15:06 | Exelixis Inc EXEL EVP and General Counsel Jeffrey Hessekiel Sold $1.6 million of Shares
2019-08-20 10:09:02 | Exelixis EXEL Stock Up 15.2% YTD on Strong Cabometyx Sales
2019-08-16 21:15:03 | Exelixis Inc EXEL President and CEO Michael Morrissey Sold $704,654 of Shares
2019-08-05 10:00:00 | Exelixis Hits Blockbuster Status
2019-08-05 07:49:54 | Is Exelixis, Inc. NASDAQ:EXEL A High Quality Stock To Own?
2019-08-03 06:04:19 | Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT
2019-08-02 23:15:22 | Exelixis Inc EXEL President and CEO Michael Morrissey Sold $709,560 of Shares
2019-08-01 10:58:56 | Exelixis Stock Rises on Revenue Beat
2019-08-01 10:50:02 | Exelixis EXEL Q2 Earnings & Sales Beat, Cabometyx Shines
2019-07-31 23:24:58 | Exelixis Inc EXEL Q2 2019 Earnings Call Transcript
2019-07-31 19:15:11 | Exelixis EXEL Q2 Earnings and Revenues Beat Estimates
2019-07-31 16:06:00 | Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update
2019-07-26 15:17:07 | Exelixis EXEL to Report Q2 Earnings: What's in the Cards?
2019-07-26 09:18:00 | 3 Cancer Treatment Stocks to Buy Right Now
2019-07-24 14:45:36 | 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar
2019-07-24 10:32:02 | Exelixis EXEL Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2019-07-22 10:10:02 | Can Exelixis EXEL Keep the Earnings Surprise Streak Alive?
2019-07-19 23:15:04 | Exelixis Inc EXEL President and CEO Michael Morrissey Sold $741,988 of Shares
2019-07-18 11:45:03 | Exelixis NASDAQ:EXEL Shareholders Have Enjoyed A Whopping 474% Share Price Gain
2019-07-18 09:30:01 | EXEL or ILMN: Which Is the Better Value Stock Right Now?
2019-07-17 16:05:00 | Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019
2019-07-17 10:06:02 | Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
2019-07-17 09:20:01 | New Strong Buy Stocks for July 17th